
Wegovy and Pregnancy: When to Stop Before Trying to Conceive
Stop Wegovy at least 2 months before a planned pregnancy, per the label. What to do if pregnant, the pill and breastfeeding, birth control and new studies.
Written by Diana Gangan. Updated November 20, 2026.
Stop Wegovy at least 2 months before you plan to get pregnant. That is the instruction in the FDA label for both the Wegovy injection and the Wegovy pill, and it exists because semaglutide, the active ingredient, leaves the body slowly: it stays in the bloodstream for about 5 to 7 weeks after the last dose. The label also says weight loss offers no benefit during pregnancy and may harm the baby, so Wegovy should be stopped as soon as a pregnancy is recognized. Human data are not enough to say whether semaglutide causes birth defects; animal studies showed harm at exposures similar to those in people. For breastfeeding, the label says the Wegovy pill is not recommended, while for the injection there are no human data. This guide covers the October 2026 guidance from the American College of Obstetricians and Gynecologists (ACOG), timing, the pill, birth control, recent studies and what to do if you become pregnant while taking Wegovy.
Wegovy and Pregnancy: The Short Answer
- 1Plan ahead: stop Wegovy at least 2 months before a planned pregnancy, whether you take the injection or the pill.
- 2Why 2 months: semaglutide has a half-life of about 1 week and remains in circulation for about 5 to 7 weeks after the last dose.
- 3If you become pregnant: stop Wegovy, tell your prescriber, and consider joining the Wegovy pregnancy registry.
- 4Breastfeeding: Wegovy tablets are not recommended; for the injection, there are no human milk data.
- 5Birth control: label data show no clinically significant effect of Wegovy tablets on two common pill hormones.
- 6Expect weight changes: observational studies link stopping GLP-1 drugs before or early in pregnancy with more weight gain during pregnancy.
How Long Before Trying to Get Pregnant Should You Stop Wegovy?
At least 2 months. Section 8.3 of the Wegovy prescribing information (revised May 2026) tells patients to discontinue Wegovy at least 2 months before a planned pregnancy because of semaglutide's long washout period. The patient Medication Guide says: "You should stop using WEGOVY 2 months before you plan to become pregnant." The Ozempic label, for the same molecule, gives the same 2-month advice.
Simple plan: pick the month you hope to start trying and count back at least two months to your last dose. Tell your prescriber first so they can plan follow-up for weight, blood pressure or blood sugar. What happens to appetite and weight after the last dose is covered in what happens when you stop taking Wegovy.
Why Does the Label Say 2 Months?
Two reasons: how long the drug lingers and what animal studies showed. According to Section 12.3 of the label, semaglutide has an elimination half-life of about 1 week, meaning about half is cleared every week. It is present in circulation for about 5 to 7 weeks after the last 2.4 mg or 7.2 mg injection or the last 25 mg tablet. A 2-month gap allows that washout to finish before conception. More on clearance is in how long Wegovy stays in your system, and the higher dose is covered in Wegovy 7.2 mg.
In animal studies in rats, rabbits and cynomolgus monkeys, semaglutide caused embryo and fetal loss, structural abnormalities and growth effects at exposures similar to those in people. These effects coincided with marked weight loss in the mothers, which may explain part of the harm. The pill's absorption enhancer, SNAC, crossed the placenta in rats, and at high doses was linked to longer pregnancies, more stillbirths and lower pup survival. Animal findings do not always apply to humans, but they are why the label takes a cautious line.
Can Wegovy Cause Birth Defects?
No one knows for sure. Section 8.1 of the label says available human data are not enough to establish whether there is a drug-associated risk of major birth defects, miscarriage or other adverse outcomes. For context, the label notes that in the general U.S. population the background risk is 2% to 4% for major birth defects and 15% to 20% for miscarriage in clinically recognized pregnancies.
The largest human study we found is reassuring but limited. Cesta and colleagues, in JAMA Internal Medicine (online 2023), looked at 51,826 infants born to mothers with type 2 diabetes in several countries, including 938 exposed to a GLP-1 drug in early pregnancy. Compared with insulin, GLP-1 exposure was not linked to more major malformations (adjusted relative risk 0.95, 95% CI 0.72 to 1.26). The mothers had diabetes rather than obesity alone, and the study did not focus on semaglutide at Wegovy doses, so it cannot rule out a risk.
What If You Get Pregnant While Taking Wegovy?
The label says to discontinue Wegovy when pregnancy is recognized if you are using it for weight reduction or cardiovascular risk reduction. For people using it for MASH (fatty liver disease with liver scarring), it should be used only if the potential benefit justifies the potential risk to the fetus. A practical checklist:
- 1Stop taking Wegovy once you know you are pregnant, unless your doctor has told you otherwise for MASH.
- 2Call your prescriber and book a prenatal visit; tell them when you took your last dose and at what strength.
- 3Do not try to lose weight during pregnancy; ask about healthy weight gain targets.
- 4Ask about blood pressure and blood sugar checks, since Wegovy may have been helping control them.
- 5Consider the Novo Nordisk pregnancy registry: 1-877-390-2760 or www.wegovypregnancyregistry.com. Registries collect outcomes to fill the gaps in human data.
Does the Wegovy Pill Change the Advice?
The FDA approved the Wegovy pill (oral semaglutide 25 mg) for weight management, as Novo Nordisk announced on December 22, 2025. The pregnancy timing advice is the same as for the injection: stop at least 2 months before a planned pregnancy, since semaglutide stays in circulation for about 5 to 7 weeks after the last tablet. The pill differs in two ways that matter for family planning: it contains SNAC, and it has strict dosing rules, including waiting at least 30 minutes before food, drinks or other oral medicines. See how to take the Wegovy pill and Wegovy pill vs injection.
Wegovy pill vs injection for pregnancy and breastfeeding (label)
Stop before planned pregnancy
At least 2 months
At least 2 months
Half-life and clearance
About 1 week; present about 5 to 7 weeks after last 25 mg tablet
About 1 week; present about 5 to 7 weeks after last 2.4 mg or 7.2 mg dose
Contains SNAC
Yes; crossed the placenta in rats
No
Breastfeeding
Not recommended; SNAC and its metabolites found in human milk
No human milk data
Oral contraceptive data
No clinically significant change with ethinyl estradiol or levonorgestrel
No contraceptive interaction data in the label subsection
Other oral medicines
Wait at least 30 minutes after the tablet
May affect absorption of oral medicines through slowed stomach emptying
Does Wegovy Affect Birth Control Pills?
Based on the label, the Wegovy pill did not cause clinically significant changes in levels of ethinyl estradiol or levonorgestrel, two hormones used in many combined birth control pills. For the injection, the label subsection on drug interactions does not include contraceptive data. More generally, Section 7.2 says Wegovy slows stomach emptying and may affect the absorption of oral medicines taken at the same time, so prescribers are told to monitor.
We did not find any Wegovy label instruction to switch birth control methods. If you take any other oral medicine, including a contraceptive pill, remember the Wegovy pill's 30-minute wait. If you have questions about your specific method, including what its own leaflet says to do after stomach upset, a pharmacist can help. Stomach side effects on the shot are covered in Wegovy nausea and on the tablets in Wegovy pill side effects.
Can Wegovy Make You More Fertile?
There is no direct evidence that Wegovy itself improves fertility. According to press reports of ACOG's October 2026 practice advisory, ACOG advises clinicians to counsel patients on reliable contraception because weight loss may increase fertility. If you are not planning a pregnancy, review your birth control as you lose weight.
What Do OB-GYNs Recommend?
ACOG published a practice advisory on GLP-1 medicines in pregnancy and lactation in October 2026. We did not read the advisory directly; as reported by Healio and Contemporary OB/GYN, it says clinicians should consider discontinuing GLP-1 drugs 1 to 2 months before conception, advises against use during pregnancy outside clinical trials, and recommends counseling on reliable contraception. For breastfeeding, it describes shared decision-making, monitoring infant weight, avoiding use with preterm infants and newborns in the first 28 days, and avoiding oral formulations if a GLP-1 is used.
Note the difference in timing: ACOG's window is "consider 1 to 2 months," while the Wegovy label says "at least 2 months." For Wegovy, follow the label unless your own doctor advises otherwise.
What Do Recent Pregnancy Studies Show?
All the studies below are observational: they compare groups of people who happened to take or stop these drugs, so they can show links but not prove cause. People who used GLP-1 drugs often differ from non-users in weight, diabetes and other risks, which adjustment can only partly correct.
Recent studies of GLP-1 drugs around pregnancy
Cesta et al., JAMA Internal Medicine, 2023
Multinational cohort; 938 GLP-1-exposed infants among 51,826 born to mothers with type 2 diabetes
No increase in major malformations vs insulin (aRR 0.95, 0.72 to 1.26)
Maya et al., JAMA, 2025
448 people who stopped a GLP-1 before or early in pregnancy vs 1,344 matched non-users
More weight gain (13.7 vs 10.5 kg), preterm birth (17% vs 13%), gestational diabetes (20% vs 15%) and hypertensive disorders (46% vs 36%)
Yu et al., Obstetrics and Gynecology, 2026
Health records; 429 pregnancy-exposed, 801 former users, 2,203 non-users
Both exposed and former users had more excess weight gain, gestational diabetes and cesarean birth than non-users; exposed and former users did not differ
Hviid et al., Human Reproduction Open, 2026
Danish registry; 756,636 pregnancies, 529 possibly exposed around conception
Most links not significant after adjustment; preterm birth higher only in women using the drugs for diabetes
Pisani et al., Endocrine, 2026
Meta-analysis of 3 cohorts; 10,880 pregnancies
No clear link with hypertensive disorders (OR 0.91, 0.57 to 1.47), with very high variation between studies
Taken together, these studies have not shown a clear rise in birth defects, but they are small for rare outcomes, mostly not specific to Wegovy doses, and cannot separate the drug from the underlying health conditions. Long-term effects of GLP-1 drugs in general are discussed in GLP-1 long-term side effects.
What Happens to Weight After Stopping Wegovy for Pregnancy?
Weight regain is likely, and it may affect the pregnancy. In the Maya study, published in JAMA in November 2025, people who stopped a GLP-1 drug before or early in pregnancy gained an average of 3.3 kg more than matched non-users, and 65% versus 49% had excess weight gain (relative risk 1.32). They also had higher rates of preterm birth (RR 1.34), gestational diabetes (RR 1.30) and hypertensive disorders (RR 1.29). The Yu study found similar patterns in former users. These findings may partly reflect higher starting weight and health risks, not only stopping the drug.
Can You Use Wegovy While Breastfeeding?
It depends on the form. According to Section 8.2 of the label, semaglutide was below the level that can be measured in human milk after Wegovy tablets, but SNAC and its metabolites were present, so breastfeeding is not recommended while taking the tablets. For the injection, there are no data on human milk; it does not contain SNAC. As reported, ACOG's advisory recommends shared decision-making, watching the baby's weight, avoiding use with preterm infants and newborns, and avoiding oral formulations.
When to Talk to Your Doctor
- 1You are planning a pregnancy in the next few months and are taking Wegovy.
- 2You have a positive pregnancy test or a missed period while on Wegovy.
- 3You want to restart Wegovy while breastfeeding, or are considering the pill.
- 4You are not planning a pregnancy and want to review your birth control as you lose weight.
- 5You have type 2 diabetes, high blood pressure or MASH and need a plan for those conditions when you stop.
- 6You have vomiting or diarrhea that does not stop while taking Wegovy.
What to Do Next: Questions to Ask Your Doctor
- 1When should my last dose be, given when I want to start trying?
- 2What should I do about my weight, blood sugar and blood pressure after I stop?
- 3Is my birth control right for me while I am on Wegovy, and does the pill form change anything?
- 4How much weight gain is healthy for me in pregnancy?
- 5If I was exposed early in pregnancy, what extra monitoring, if any, do you recommend?
- 6Can I restart Wegovy after the baby is born, and how does breastfeeding affect that choice?
If you are still adjusting doses, our Wegovy dosing schedule explains the steps.
The Bottom Line
If you are planning a pregnancy, stop Wegovy at least 2 months beforehand, whether you use the injection or the pill, and stop as soon as you learn you are pregnant. Human data are too limited to rule out harm, and animal studies showed effects on the fetus. Breastfeeding is not recommended with the Wegovy pill, and there are no human milk data for the injection. ACOG's October 2026 advisory, as reported, broadly agrees and stresses reliable contraception because weight loss may increase fertility. Plan with your doctor for weight, blood sugar and blood pressure after you stop, since observational studies link stopping with more weight gain in pregnancy.
FAQ
Semaglutide has a half-life of about 1 week and remains in circulation for about 5 to 7 weeks after the last dose, according to the label. That is why the label says to stop at least 2 months before a planned pregnancy.
Human data are not enough to know. Animal studies showed fetal harm at exposures similar to those in people, alongside maternal weight loss. A large study of mothers with type 2 diabetes found no increase in major malformations with GLP-1 drugs compared with insulin.
Label data show the Wegovy pill caused no clinically significant change in ethinyl estradiol or levonorgestrel levels. The label has no contraceptive data for the injection and does not tell users to switch methods. Ask a pharmacist about your specific method.
The label says breastfeeding is not recommended with Wegovy tablets because SNAC passes into milk. There are no human milk data for the injection. Discuss it with your doctor and your baby's pediatrician.
Stop Wegovy, contact your prescriber and book prenatal care. Tell them the date and strength of your last dose. You can also report the pregnancy to the Wegovy pregnancy registry at 1-877-390-2760.
There is no direct evidence that Wegovy itself does. ACOG, as reported in the medical press, notes that weight loss may increase fertility and advises counseling on reliable contraception.
Sources
- 1Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information (revised 05/2026), U.S. Food and Drug Administration, 2026
- 2Novo Nordisk. OZEMPIC (semaglutide) injection, prescribing information (revised 05/2026), U.S. Food and Drug Administration, 2026
- 3Wegovy prescribing information and Medication Guide (mirror, revised 6/2026), Drugs.com, 2026
- 4Novo Nordisk announcement of FDA approval of the Wegovy pill, Novo Nordisk, 2025
- 5Cesta CE et al. Multinational cohort study of GLP-1 receptor agonists in early pregnancy and major malformations, JAMA Internal Medicine, 2023
- 6Yu et al. Cohort study of semaglutide use before and during pregnancy, gestational weight gain and pregnancy outcomes, Obstetrics and Gynecology, 2026
- 7Hviid KVR et al. Danish registry study of periconceptional GLP-1 receptor agonist exposure and pregnancy outcomes, Human Reproduction Open, 2026
- 8News report on ACOG guidance on GLP-1 medicines during pregnancy and lactation, Healio, 2026
- 9News report on ACOG's GLP-1 receptor agonist pregnancy and lactation guidance, Contemporary OB/GYN, 2026
- 10News report on the JAMA cohort study of stopping GLP-1 drugs before or early in pregnancy (Maya et al.), AJMC, 2025
- 11News report on a meta-analysis of GLP-1 drugs and hypertensive disorders of pregnancy (Pisani et al., Endocrine), Drug Topics, 2026
This article is general information based on FDA labels, published studies and news reports, and it is not a substitute for advice from a doctor or midwife. Wegovy and Ozempic are made by Novo Nordisk, which also runs the pregnancy registry; the ACOG advisory is summarized from press reports.

Diana Gangan
Author
Comments (0)
Be the first to comment on this article.




